Bronchopulmonary Dysplasia in Premature Infants: Pathogenesis, Clinical Picture, Treatment and Prevention (Part 2)

V.I. Snysar, O.I. Obolonsky, D.M. Surkov, O.G. Kapustina, D.G. Volkov

Abstract


The article describes the current views on the pathogenesis, clinical picture, diagnosis and treatment of bronchopulmonary dysplasia. Special attention is paid to the influence of ductus arteriosus on the occurrence and severity of bronchopulmonary dysplasia, to the mechanisms of the hemodynamic effects of patent ductus arteriosus on blood flow in the anterior cerebral artery, the vessels of the pulmonary circulation, the impact of patent duct on the development of pulmonary edema. Separately, the methods for closure of patent ductus arteriosus were considered. The advantages of pharmacologic ductal closure are noted.


Keywords


bronchopulmonary dysplasia; pathogenesis; clinical picture; diagnosis; prevention; ductus arteriosus; cyclooxygenase inhibitors; premature newborns

References


Bose C.L., Laughon M.M. Patent ductus arteriosus: lack of evidence for common treatments // Arch. Dis. Child. Fetal Neonatal Ed. — 2007. — 92(6). — 498-502.

Herrman K. et al. Spontaneous Closure of the Patent Ductus Arteriosus in Very Low Birth Weight Infants Following Discharge from the Neonatal Unit // Arch. Dis. Child Fetal. Neonatal Ed. doi: 10.1136. Abstract.

Gersony W.M., Peckham G.J., Ellison R.C. et al. Effects of indomethacin in premature infants with patent ductus arteriosus: the results of a national collaborative trial // J. Pediatr. — 1983. — 102. — 895-906.

Cassady G., Crouse D.T., Kirklin J.W. et al. A randomised controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth // N. Engl. J. Med. — 1989. — 320. — 1511-6.

Kabra N.S., Schmidt B., Roberts R.S., Doyle L.W., Papile L. et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms // J. Pediatr. — 2007. — 150(3). — 229-34.

Chorne N., Leonard С., Piecuch R., Clyman R.I. Patent Ductus Arteriosus and Its Treatment as Risk Factors for Neonatal and Neurodevelopmental Morbidity // Pediatrics. — 2007. — 119. — 1165-71.

Mosca F., Bray M., Lattanzio M. et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus // J. Pediatr. — 1997. — 131. — 549-54.

Kluckow M., Evans N. Low superior vena cava flow and intraventricular hemorrhage in preterm infants // Arch. Dis. Child. — 2000. — 82. — 188-94.

Володин Н.Н., Байбарина Е.Н. Протокол ведения недоношенных детей с гемодинамически значимым функционирующим артериальным протоком. — М., 2009. — 34 с.

Knight D.B. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials // Semin. Neonatol. — 2001. — 6. — 63-73.

Pezzati M., Vangi V., Biagiotti R. et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus // J. Pediatr. — 1999. — 135. — 733-78.

Van Overmeire B., Smets K., Lecoutere D. et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus // N. Engl. J. Med. — 2000. — 43. — 674-81.

Ohlsson A., Walia R., Shah S.S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants (Review) // Cochrane Database Syst. Rev. — 2008. — Issue 1(1): CD003481.

Aly H., Lotfy W., Badrawi N., Ghawas M. et al. Oral Ibuprofen and Ductus Arteriosus in Premature Infants: A Randomized Pilot Study. Chotigeat U., Jirapapa K., Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in premature infants // J. Med. Assoc. Thailand. — 2003. — 86. — 563-9.

Erdeve O., Sarici U., Sari E., Gok F. Oral-ibuprofen-induced acute renal failure in a preterm infant // Pediatr. Nephrol. — 2008. — 23. — 1565-7.

Tatli M.M., Kumral A., Duman N. et al. Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very low birth weight infants // Acta Paediatr. — 2004. — 93. — 999-1001.

Van Overmeire B., Van de Broek H., Van Laer P. et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome // J. Pediatr. — 2001. — 138. — 205-11.

Schmidt B., Roberts R.S., Davis P., Doyle L.W., Barrington K.J., Ohlsson A., Solimano A., Tin W. Caffeine therapy for apnea of prematurity // N. Engl. J. Med. — 2006. — Vol. 354. — P. 2112-2121.

Urlichs F., Speer C.P. Neutrophil function in preterm and term infants // Neoreviews. — 2004. — Vol. 10. — P. e417-e429.

Brion L.P., Bell E.F., Raghuveer T.S. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants // Cochrane Database Syst. Rev. 2003: CD003665.

Sandberg K., Fellman V., Stigson L., Thiringer K., Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants // Biol. Neonate. — 2004. — Vol. 86. — P. 275-279.

Ahola T., Lapatto R., Raivio K.O., Selander B., Stigson L., Jonsson B., Jonsbo F., Esberg G., Stovring S., Kjartansson S., Stiris T., Lossius K., Virkola K., Fellman V. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: A randomi­zed controlled trial // J. Pediatr. — 2003. — Vol. 143. — P. 713-719.

Davis J.M., Parad R.B., Michele T., Allred E., Price A., Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase // Pediatrics. — 2003. — Vol. 111. — P. 469-476.

Shenai J.P. Vitamin A supplementation in very low birth weight neonates: Rationale and evidence // Pediatrics. — 1999. — Vol. 104. — P. 1369-1374.

Spears K., Cheney C., Zerzan J. Low plasma retinol concentrations increase the risk of developing bronchopulmonary dysplasia and long-term respiratory disability in very-low-birth-weight infants // The American journal of clinical nutrition. — 2004. — Vol. 80. — P. 1589-1594.

Tyson J.E., Wright L.L., Oh W., Kennedy K.A., Mele L., Ehrenkranz R.A., Stoll B.J., Lemons J.A., Stevenson D.K., Bauer C.R., Korones S.B., Fanaroff A.A. Vitamin A supplementation for extremely-low-birth-weight infants. National institute of child health and human development neonatal research network // N. Engl. J. Med. — 1999. — Vol. 340. — P. 1962-1968.

Wardle S.P., Hughes A., Chen S., Shaw N.J. Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease // Arch. Dis. Child Fetal Neonatal Ed. — 2001. — Vol. 84. — P. F9-F13.

Darlow B.A., Graham P.J. Vitamin a supplementation to prevent mortality and short- and long-term morbidity in very low birthweight infants // Cochrane Database Syst. Rev. 2011: CD000501.

Ambalavanan N., Tyson J.E., Kennedy K.A., Hansen N.I., Vohr B.R., Wright L.L., Carlo W.A. and National Institute of Child Health and Human Development Neonatal Research N. Vitamin a supplementation for extremely low birth weight infants: Outcome at 18 to 22 months // Pediatrics. — 2005. — Vol. 115. — P. e249-254.

Ambalavanan N., Kennedy K., Tyson J., Carlo W. A. Survey of vitamin A supplementation for extremely-low-birthweight infants: Is clinical practice consistent with the evidence? // J. Pediatr. — 2004. — Vol. 145. — P. 304-307.

The Neonatal Inhaled Nitric Oxide Study Group: Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure // N. Engl. J. Med. — 1997. — Vol. 336. — P. 597-604.

Kinsella J.P., Abman S.H. Inhaled nitric oxide in the premature newborn // J. Pediatr. — 2007. — Vol. 151. — P. 10-15.

Kinsella J.P., Cutter G.R., Walsh W.F., Gerstmann D.R., Bose C.L., Hart C., Sekar K.C., Auten R.L., Bhutani V.K., Gerdes J.S., George T.N., Southgate W.M., Carriedo H., Couser R.J., Mammel M.C., Hall D.C., Pappagallo M., Sardesai S., Strain J.D., Baier M., Abman S.H. Early inhaled nitric oxide therapy in premature newborns with respiratory failure // N. Engl. J. Med. — 2006. — Vol. 355. — P. 354-364.

Kinsella J.P., Walsh W.F., Bose C.L., Gerstmann D.R., Labella J.J., Sardesai S., Walsh-Sukys M.C., McCaffrey M.J., Cornfield D.N., Bhutani V.K., Cutter G.R., Baier M., Abman S.H. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: A randomised controlled trial // Lancet. — 1999. — Vol. 354. — P. 1061-1065.

Schreiber M.D., Gin-Mestan K., Marks J.D., Huo D., Lee G., Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome // N. Engl. J. Med. — 2003. — Vol. 349. — P. 2099-2107.

Van Meurs K.P., Wright L.L., Ehrenkranz R.A., Lemons J.A., Ball M.B., Poole W.K., Perritt R., Higgins R.D., Oh W., Hudak M.L., Laptook A.R., Shankaran S., Finer N.N., Carlo W.A., Kennedy K.A., Fridriksson J.H., Steinhorn R.H., Sokol G.M., Konduri G.G., Aschner J.L., Stoll B.J., D’Angio C.T., Stevenson D.K. Inhaled nitric oxide for premature infants with severe respiratory failure // N. Engl. J. Med. — 2005. — Vol. 353. — P. 13-22.

Ballard R.A., Truog W.E., Cnaan A., Martin R.J., Ballard P.L., Merrill J.D., Walsh M.C., Durand D.J., Mayock D.E., Eichenwald E.C., Null D.R., Hudak M.L., Puri A.R., Golombek S.G., Courtney S.E., Stewart D.L., Welty S.E., Phibbs R.H., Hibbs A.M., Luan X., Wadlinger S.R., Asselin J.M., Coburn C.E. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation // N. Engl. J. Med. — 2006. — Vol. 355. — P. 343-353.

Hascoet J.M., Fresson J., Claris O., Hamon I., Lombet J., Liska A., Cantagrel S., Al Hosri J., Thiriez G., Valdes V. The safety and efficacy of nitric oxide therapy in premature infants // J. Pediatr. — 2005. — Vol. 146. — P. 318-323.

Subhedar N.V., Ryan S.W., Shaw N.J. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants // Arch. Dis. Child Fetal Neonatal Ed. — 1997. — Vol. 77. — P. F185-190.

Dani C., Bertini G., Pezzati M., Filippi L., Cecchi A., Ru­baltelli F.F. Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome // Acta Paediatr. — 2006. — Vol. 95. — P. 1116-1123.

Mercier J.C., Hummler H., Durrmeyer X., Sanchez-Luna M., Carnielli V., Field D., Greenough A., Van Overmeire B., Jonsson B., Hallman M., Baldassarre J. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (euno): A randomised controlled trial // Lancet. — 2010. — Vol. 376. — P. 346-354.

Askie L.M., Ballard R.A., Cutter G.R., Dani C., Elbourne D., Field D., Hascoet J.M., Hibbs A.M., Kinsella J.P., Mercier J.C., Rich W., Schreiber M.D., Wongsiridej P.S., Subhedar N.V., Van Meurs K.P., Voysey M., Barrington K., Ehrenkranz R.A., Finer N.N. Inhaled nitric oxide in preterm infants: An individual-patient data meta-analysis of randomized trials // Pediatrics. — 2011. — Vol. 128.— P. 729-739.

Groneck P., Reuss D., Goetze-Speer B., Speer C.P. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease // J. Pediatr. — 1993. — Vol. 122. — P. 938-944.

Gladstone I.M., Ehrenkranz R.A., Jacobs H.C. Pulmonary function tests and fluid balance in neonates with chronic lung disease during dexamethasone treatment // Pediatrics. — 1989. — Vol. 84. — P. 1072-1076.

Halliday H.L., Ehrenkranz R.A., Doyle L.W. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants // Cochrane Database Syst Rev. 2009: CD001146.

Halliday H.L., Ehrenkranz R.A., Doyle L.W.: Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants // Cochrane Database Syst. Rev. 2009: CD001145.

Watterberg K.L., Gerdes J.S., Cole C.H., Aucott S.W., Thilo E.H., Mammel M.C., Couser R.J., Garland J.S., Rozycki H.J., Leach C.L., Backstrom C., Shaffer M.L. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: A multicenter trial // Pediatrics. — 2004. — Vol. 114. — P. 1649-1657.

Doyle L.W., Ehrenkranz R.A., Halliday H.L. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: A systematic review // Neonatology. — 2010. — Vol. 98. — P. 111-117.

Pantalitschka T., Poets C.F. Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia // Pediatr. Pul­monol. — 2006. — Vol. 41. — P. 703-708.

Shah S.S., Ohlsson A., Halliday H., Shah V.S. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants // Cochrane Database Syst. Rev. 2007: CD002057.

Bassler D., Halliday H.L., Plavka R., Hallman M., Shinwell E.S., Jarreau P.H., Carnielli V., van den Anker J., Schwab M., Poets C.F. The neonatal European study of inhaled steroids (neurosis): An eu-funded international randomised controlled trial in preterm infants // Neonatology. — 2010. — Vol. 97. — P. 52-55.

Saugstad O.D. Oxygen and oxidative stress in bronchopulmonary dysplasia // J. Perinat. Med. — 2010. — Vol. 38. — P. 571-577.

Saugstad O.D., Aune D. In search of the optimal oxygen sa­turation for extremely low birth weight infants: A systematic review and meta-analysis // Neonatology. — 2011. — Vol. 100. — P. 1-8.

Carlo W.A., Finer N.N., Walsh M.C., Rich W., Gantz M.G., Laptook A.R., Yoder B.A., Faix R.G., Das A., Poole W.K., Schibler K., Newman N.S., Ambalavanan N., Frantz I.D., 3rd, Piazza A.J., Sanchez P.J., Morris B.H., Laroia N., Phelps D.L., Poindexter B.B., Cotten C.M., Van Meurs K.P., Duara S., Narendran V., Sood B.G., O’Shea T.M., Bell E.F., Ehrenkranz R.A., Watterberg K.L., Higgins R.D. Target ranges of oxygen saturation in extremely preterm infants // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1959-1969.

Stenson B., Brocklehurst P., Tarnow-Mordi W. Increased 36 week survival with high oxygen saturation target in extremely preterm infants // N. Engl. J. Med. — 2011. — Vol. 364. — P. 1680-1682.

Saugstad O.D., Speer C.P., Halliday H.L. Oxygen saturation in immature babies: Revisited with updated recommendations // Neonatology. — 2011. — Vol. 100. — P. 217-218.

Groneck P., Goetze-Speer B., Speer C. Inflammatory bronchopulmonary response of preterm infants with microbial colonization of the airways at birth // Arch. Dis. Child Fetal Neonatal Ed. — 1996. — Vol. 74. — P. F51-55.

Schelonka R.L., Katz B., Waites K.B., Benjamin D.K., Jr. Critical appraisal of the role of ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques // Pediatr. Infect. Dis. J. —2005. — Vol. 24. — P. 1033-1039.

Jonsson B., Rylander M., Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates // Acta Paediatr. — 1998. — Vol. 87. — P. 1079-1084.

Lyon A.J., McColm J., Middlemist L., Fergusson S., McIntosh N., Ross P.W. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants // Arch. Dis. Child Fetal Neonatal Ed. — 1998. — Vol. 78. — P. F10-14.

Baier R.J., Loggins J., Kruger T. Failure of erythromycin to eliminate airway colonization with Ureaplasma urealyticum in very low birth weight infants // MC Pediatrics. — 2003. — Vol. 3. — P. 10.

Matlow A., Th’ng C., Kovach D., Quinn P., Dunn M., Wang E. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents // Antimicrob. Agents Chemother. — 1998. — Vol. 42. — P. 1290-1292.

Aghai Z.H., Kode A., Saslow J.G., Nakhla T., Farhath S., Stahl G.E., Eydelman R., Strande L., Leone P., Rahman I. Azithromycin suppresses activation of nuclear factor-kappa b and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants // Pediatr. Res. — 2007. — Vol. 62. — P. 483-488.

Ballard H.O., Shook L.A., Bernard P., Anstead M.I., Kuhn R., Whitehead V., Grider D., Crawford T.N., Hayes D. Jr. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: A randomized, double-blind, placebo controlled trial // Pediatr. Pulmonol. — 2011. — Vol. 46. — P. 111-118.

Stewart A., Brion L.P. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease // Cochrane Database Syst. Rev. 2011: CD001453.

Stewart A., Brion L.P., Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease // Cochrane Database Syst. Rev 2011: CD001817.

Ng G.Y., Da S., Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants // Cochrane Database Syst. Rev. 2001: CD003214.

Avery M., Tooley W., Keller J., Hurd S., Bryan M., Cotton R., Epstein M., Fitzhardinge P., Hansen C., Hansen T. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers // Pediatrics. — 1987. — Vol. 79. — P. 26-30.

Morley C.J., Davis P.G., Doyle L.W., Brion L.P., Hascoet J.M., Carlin J.B. Nasal CPAP or intubation at birth for very preterm infants // N. Engl. J. Med. — 2008. — Vol. 358. — P. 700-708.

Finer N.N., Carlo W.A., Walsh M.C., Rich W., Gantz M.G., Laptook A.R., Yoder B.A., Faix R.G., Das A., Poole W.K., Donovan E.F., Newman N.S., Ambalavanan N., Frantz I.D., 3rd, Buchter S., Sanchez P.J., Kennedy K.A., Laroia N., Poindexter B.B., Cotten C.M., Van Meurs K.P., Duara S., Narendran V., Sood B.G., O’Shea T.M., Bell E.F., Bhandari V., Watterberg K.L., Higgins R.D. Early CPAP versus surfactant in extremely preterm infants // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1970-1979.

Cherif A. Hachani C., Khrouf N. Risk factors of the failure of surfactant treatment by transient intubation during nasal continuous positive airway pressure in preterm infants // Am. J. Perinatol. — 2008. — Vol. 25(10). — P.647-652.

Dargaville P.A. OPTIMIST-A. Multicentre randomized controlled trial of minimally-invasive surfactant therapy in preterm infants 25–28 weeks gestation on continuous positive airway pressure. — 2011. — http://www.anzctr.org.au/ACTRN12611000916943.aspx

Fuchs H., Lindner W., Leiprecht A. et al. Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of < 29 weeks gestational age // Arch. Dis. Child. Fetal Neonatal Ed. — 2011. — Vol. 96. — P. 343-347

Dargaville P.A., Aiyappan A., Cornelius A. et al. Preliminary evaluation of a new technique of minimally invasive surfactant therapy // Arch. Dis. Child. Fetal Neonatal Ed. — 2011. — Vol. 96. — P. 243-248

El-Dib M., Narang S. et al. Red blood cell transfusion, feeding and necrotizing enterocolitis in preterm infants // Journal of Perinatology. — 2011. — Vol. 31. — P. 183-187.

Gien J. Controversies in the management of patent ductus arteriosus // NeoReviews. — 2008. — Vol. 9. — e477-e482.

Bhandari V. Using early (S)NIPPV, with or without surfactant administration, especially in the youngest infants at the highest risk for adverse outcome // J. Perinatol. — 2010. — Vol. 30. — P. 505.

Bhandari V., Finer N.N. et al. Synchronized nasal intermittent positive-pressure ventilation and neonatal // J. Pediatr. — 2009. — Vol. 124. — P. 517-526.

Kugelman A., Durand M. A comprehensive approach to the prevention of bronchopulmonary dysplasia // Pediatr. Pulmonol. — 2011. — Vol. 46. — P. 1153-1165.

Wheeler K.I., Klingenberg C., Morley C.J., Davis P.G. Volume-targeted versus pressure-limited ventilation for preterm infants: A systematic review and meta-analysis // Neonatology. — 2011. — Vol. 100. — P. 219-227.

Carlo W.A., Stark A.R., Wright L.L., Tyson J.E., Pa­pile L.A., Shankaran S., Donovan E.F., Oh W., Bauer C.R., Saha S., Poole W.K., Stoll B. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants// J. Pediatr. — 2002. — Vol. 141. — P. 370-374.

Thome U.H., Carlo W.A., Pohlandt F. Ventilation strategies and outcome in randomised trials of high frequency ventilation // Arch. Dis. Child Fetal Neonatal Ed. — 2005. — Vol. 90. — P. F466-473.

Geary C., Caskey M., Fonseca R., Malloy M. Decreased incidence of bronchopulmonary dysplasia after early management changes, including surfactant and nasal continuous positive airway pressure treatment at delivery, lowered oxygen saturation goals, and early amino acid administration: A historical cohort study // Pediatrics. — 2008. — Vol. 121.

Wolfgang Thomas, Christian P. Speer. Preventive and therapeutic approaches for bronchopulmonary dysplasia — an update. 2012.




DOI: https://doi.org/10.22141/2224-0551.5.48.2013.84826

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru